Literature DB >> 21938529

R-flurbiprofen, a novel nonsteroidal anti-inflammatory drug, decreases cell proliferation and induces apoptosis in pituitary adenoma cells in vitro.

James K Liu1, Smruti K Patel, David L Gillespie, Kum Whang, William T Couldwell.   

Abstract

R-flurbiprofen, a nonsteroidal anti-inflammatory drug derivative, has been shown to inhibit colonic adenoma formation in mice. We investigated the effects of R-flurbiprofen on cell proliferation and apoptosis in pituitary adenoma cell lines. GH4C1 rat pituitary cell line cultures and low-passage human primary pituitary cell cultures were treated with varying concentrations of R-flurbiprofen (0.1-1.0 mM). R-flurbiprofen inhibited cell proliferation in a dose-dependent fashion. A terminal deoxynucleotidyl transferase dUTP nick end labeling assay and chromatin condensation/dead cell apoptosis assay demonstrated induction of apoptosis at higher concentrations of R-flurbiprofen. R-flurbiprofen decreases cell proliferation and induces apoptosis in pituitary adenoma cells in vitro. This may be a potential therapy in the management of pituitary adenoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21938529     DOI: 10.1007/s11060-011-0712-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  56 in total

1.  Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.

Authors:  Brian T Ragel; Randy L Jensen; David L Gillespie; Stephen M Prescott; William T Couldwell
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

2.  Inhibition of noxious stimulus-induced spinal prostaglandin E2 release by flurbiprofen enantiomers: a microdialysis study.

Authors:  G Geisslinger; U Muth-Selbach; O Coste; G Vetter; A Schrödter; H G Schaible; K Brune; I Tegeder
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

3.  Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.

Authors:  M K Jones; H Wang; B M Peskar; E Levin; R M Itani; I J Sarfeh; A S Tarnawski
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

4.  Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.

Authors:  B S Reddy; Y Hirose; R Lubet; V Steele; G Kelloff; S Paulson; K Seibert; C V Rao
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

5.  Host cyclooxygenase-2 modulates carcinoma growth.

Authors:  C S Williams; M Tsujii; J Reese; S K Dey; R N DuBois
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

6.  Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells.

Authors:  J Shao; T Fujiwara; Y Kadowaki; T Fukazawa; T Waku; T Itoshima; T Yamatsuji; M Nishizaki; J A Roth; N Tanaka
Journal:  Oncogene       Date:  2000-02-10       Impact factor: 9.867

7.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

8.  Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas.

Authors:  W T Couldwell; M H Weiss; R E Law; D R Hinton
Journal:  J Neurosurg       Date:  1995-03       Impact factor: 5.115

9.  Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.

Authors:  Brian R Budenholzer
Journal:  BMJ       Date:  2002-07-20

10.  A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity.

Authors:  P R Twentyman; M Luscombe
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more
  3 in total

1.  Expression of AGR2 in pituitary adenomas and its association with tumor aggressiveness.

Authors:  Mamatemin Tohti; Junyang Li; Chiyuan Ma; Wanchun Li; Zhenfeng Lu; Yuebing Hu
Journal:  Oncol Lett       Date:  2015-09-21       Impact factor: 2.967

2.  High enantioselective Novozym 435-catalyzed esterification of (R,S)-flurbiprofen monitored with a chiral stationary phase.

Authors:  Tomasz Siódmiak; Debby Mangelings; Yvan Vander Heyden; Marta Ziegler-Borowska; Michał Piotr Marszałł
Journal:  Appl Biochem Biotechnol       Date:  2015-01-06       Impact factor: 2.926

3.  Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.

Authors:  Tudor I Oprea; Larry A Sklar; Jacob O Agola; Yuna Guo; Melina Silberberg; Joshua Roxby; Anna Vestling; Elsa Romero; Zurab Surviladze; Cristina Murray-Krezan; Anna Waller; Oleg Ursu; Laurie G Hudson; Angela Wandinger-Ness
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.